|
Alaunos Therapeutics, Inc. (TCRT) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Alaunos Therapeutics, Inc. (TCRT) Bundle
Découvrez la vraie valeur d'Aaunos Therapeutics, Inc. (TCRT) avec notre calculatrice avancée DCF! Ajustez les hypothèses clés, explorez divers scénarios et évaluez comment les changements affectent la valorisation d'Alaunos Therapeutics, Inc. (TCRT) - le tout dans un modèle Excel pratique.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .4 | 2.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 634.17 | -99.83 | 0.04277892 | 0.04277892 | 0.04277892 | 0.04277892 | 0.04277892 |
| EBITDA | -117.2 | -78.8 | -75.0 | -31.8 | -30.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | -18837.19 | -1088.88 | -618080 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .6 | 1.1 | 2.6 | 2.8 | 2.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 652.51 | 94.42 | 46300 | 98.88 | 98.88 | 98.88 | 98.88 | 98.88 |
| EBIT | -117.8 | -80.0 | -77.6 | -34.6 | -33.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | -19489.7 | -1183.3 | -664380 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 79.7 | 115.1 | 76.1 | 39.1 | 6.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 3.3 | 4.7 | 1.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 279.15 | 0.13689 | 20 | 64.03 | 64.03 | 64.03 | 64.03 | 64.03 |
| Inventories | .0 | .0 | .0 | 13.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 0 | 477 | 0 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | .9 | 1.0 | 1.4 | 1.4 | .6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 343.72 | 47.54 | 12320 | 89.51 | 89.51 | 89.51 | 89.51 | 89.51 |
| Capital Expenditure | -.3 | -9.8 | -3.3 | -.2 | -.2 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | -834.92 | -7.39 | -3940 | -41.48 | -41.48 | -41.48 | -41.48 | -41.48 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -177.9 | -78.8 | -75.7 | -34.5 | -33.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -180.0 | -88.8 | -72.5 | -44.7 | -17.9 | -.6 | .0 | .0 | .0 | .0 |
| WACC, % | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -6 | |||||||||
| Equity Value | 6 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 3.46 |
What You Will Get
- Real Alaunos Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Alaunos Therapeutics, Inc. (TCRT).
- Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on Alaunos’ fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections.
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility.
Key Features
- Customizable Clinical Parameters: Adjust key metrics such as patient response rates, treatment costs, and trial durations.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other important financial metrics.
- Industry-Leading Precision: Incorporates Alaunos Therapeutics’ real-world data for accurate valuation results.
- Effortless Scenario Analysis: Easily evaluate various assumptions and analyze their impacts on outcomes.
- Efficiency Booster: Avoid the complexities of developing intricate valuation models from the ground up.
How It Works
- Step 1: Download the financial analysis Excel file for Alaunos Therapeutics, Inc. (TCRT).
- Step 2: Review the pre-filled financial data and projections specific to Alaunos Therapeutics.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (marked cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the results and leverage the findings for your investment strategies.
Why Choose This Calculator for Alaunos Therapeutics, Inc. (TCRT)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and biotech professionals.
- Comprehensive Data: Alaunos Therapeutics’ historical and projected financials are preloaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions to inform your decisions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and other essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Investors: Evaluate Alaunos Therapeutics’ (TCRT) valuation to make informed stock decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation processes of biotech firms like Alaunos Therapeutics.
- Consultants: Provide comprehensive valuation analyses and reports for clients in the healthcare sector.
- Students and Educators: Utilize real-time industry data to teach and learn valuation strategies.
What the Alaunos Therapeutics Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Alaunos Therapeutics.
- Real-World Data: Alaunos Therapeutics’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into financial health.
- Key Ratios: Integrated analysis for assessing profitability, efficiency, and leverage specific to Alaunos Therapeutics.
- Dashboard with Visual Outputs: Visualizations including charts and tables to present clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.